Select a category to explore research frontiers
Loading categories...
Design and modification of exosomes and microvesicles as natural delivery vehicles for therapeutic proteins and nucleic acids.
Current EV loading methods rely on passive diffusion or non-specific electroporation, limiting precise therapeutic cargo delivery. This frontier explores CRISPR-based active loading systems that enable dynamic, reversible cargo packaging with single-molecule specificity.
The fate of engineered EVs post-administration remains poorly characterized, with limited ability to distinguish therapeutic degradation from immunological clearance. This research gap addresses the urgent need for non-invasive, multiplexed tracking systems that decode EV stability kinetics in vivo.
Natural EVs are constrained by cellular heterogeneity and donor-dependent variability; engineered alternatives must achieve precise control over size, protein composition, and immune activation. This frontier explores cell-free biofabrication of EVs with rationally designed protein scaffolds.
Current EV targeting strategies rely on single-ligand approaches with poor specificity; multi-organ accumulation limits efficacy and increases toxicity. This frontier integrates high-throughput surface modification libraries with AI-driven models to predict optimal ligand combinations for organ-selective delivery.
Therapeutic EV research is predominantly limited to mammalian sources, overlooking plant and bacterial EVs with distinct immunogenic profiles and inherent biocompatibility. This frontier explores systematic engineering of non-mammalian EVs as novel therapeutic delivery vehicles.
Current EV delivery in tissue engineering relies on bulk loading in scaffolds, lacking spatial and temporal control necessary for complex tissue regeneration. This frontier develops smart hydrogels that create programmed EV release gradients mimicking developmental morphogen patterns.
The combinatorial space of possible EV surface modifications exceeds experimental screening capacity; AI-guided design is essential to identify optimal modification patterns for specific therapeutic outcomes. This frontier implements machine learning platforms to accelerate EV optimization cycles.
microRNA dysregulation drives numerous pathologies, yet current therapeutic approaches lack tissue specificity and biocompatibility. This frontier engineers EVs as tunable competing endogenous RNA (ceRNA) platforms that sequester disease-associated miRNAs with programmable capacity and selectivity.